Liver, Pancreas, and Biliary TractNonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities☆,☆☆,★
Section snippets
Subjects studied
The studies were performed in patients with NASH who did not have severe morbid obesity (body mass index [BMI] > 40), gastric bypass, diabetes, or cirrhosis (test group) and compared with 2 other groups: (1) age-, gender-, and weight-matched controls with fatty liver alone that was not associated with alcohol, medications, morbid obesity, or gastric bypass surgery; and (2) gender-matched normal controls. NASH was diagnosed using a combination of commonly used histologic and clinical criteria2
Results
A total of 6 subjects each with NASH and fatty liver were studied (Table 1) and compared with 6 lean normal controls.The normal controls were significantly younger (P < 0.01, Kruskal–Wallis ANOVA) than those with NASH or fatty liver alone. The BMI and body fat content of normal subjects were less (P < 0.02, Kruskal–Wallis ANOVA) than those with NASH or fatty liver. Although the BMI of subjects with fatty liver was similar to that of subjects with NASH, the body fat content of those with NASH
Discussion
Obesity and diabetes are the 2 best-known risk factors for the development of both fatty liver and NASH.1 Both risk factors are associated with insulin resistance14 and are considered components of syndrome X.13, 14, 32 The present study confirms that insulin resistance is uniformly present in subjects with fatty liver or NASH, even in the absence of diabetes, and extends the spectrum of the syndrome to include both of these conditions.
According to our original hypothesis, it was predicted that
References (47)
- et al.
Nonalcoholic steatohepatitis: an expanded clinical entity
Gastroenterology
(1994) - et al.
The natural history of nonalcoholic fatty liver: a follow-up study
Hepatology
(1995) - et al.
The association of cardiovascular risk factor clustering related to insulin resistance syndrome (syndrome X) between young parents and their offspring: the Bogalusa Heart Study
Atherosclerosis
(1999) - et al.
Association of non-alcoholic fatty liver disease with insulin resistance
Am J Med
(1999) - et al.
Glucose and insulin metabolism in cirrhosis
J Hepatol
(1989) - et al.
Protein measurement with the Folin phenol reagent
J Biol Chem
(1951) - et al.
A simple method for isolation and purification of total lipids from animal tissues
J Biol Chem
(1957) - et al.
Mitochondrial abnormalities in non-alcoholic steatohepatitis
J Hepatol
(1999) - et al.
Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection
Pathology
(1992) - et al.
The glucosefatty acid cycle: its role in insulin sensitivity and the metabolic disturbances in diabetes mellitus
Lancet
(1963)
Metazoan cytochrome P450 evolution
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease
Mayo Clin Proc
The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years
Hepatology
Review: nonalcoholic steatohepatitis
J Gastroenterol Hepatol
Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions
Am J Gastroenterol
Nonalcoholic steatonecrosis: a unique histopathologic lesion of the liver with multiple causes
Surv Dig Dis
Liver morphology and function tests in obesity and during total starvation
Am J Dig Dis
Five patients with nonalcoholic diabetic cirrhosis
Acta Hepatogastroenterol Stuttg
Two cases from the spectrum of nonalcoholic steatohepatitis
J Clin Gastroenterol
Nonalcoholic steatohepatitis
Ann Intern Med
Syndrome X: 10 years after
Drugs
Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease
Diabetes Care
The relationship between fatty liver and hyperinsulinemia in obese Japanese children
J Pediatr Gastroenterol Nutr
Cited by (1868)
Loss of mitochondrial adaptation associates with deterioration of mitochondrial turnover and structure in metabolic dysfunction-associated steatotic liver disease
2024, Metabolism: Clinical and ExperimentalAnthocyanins: Potential phytochemical candidates for the amelioration of non-alcoholic fatty liver disease
2024, Annales Pharmaceutiques FrancaisesHepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease
2024, Trends in Pharmacological SciencesRoles of immune dysregulation in MASLD
2024, Biomedicine and Pharmacotherapy
- ☆
Supported in part by National Instututes of Health grants DK 02755 (to A.J.S.) and DK 43013 (to J.N.C.) and by grant MO1 RR 00065-38 to the General Clinical Research Center at the Virginia Commonwealth University-Medical College of Virginia.
- ☆☆
Address requests for reprints to: Arun J. Sanyal, M.D., MCV Box 980711, Medical College of Virginia, Richmond, Virginia 23298-0711. e-mail: [email protected]; fax: (804) 828-2037.
- ★
Previously published in abstract form (Gastroenterology 1999;116:1271A) and presented at the annual meeting of the American Association for Study of Liver Disease in Orlando, Florida, 1999.